Literature DB >> 24192120

Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study.

Kei Kamide1, Kei Asayama, Tomohiro Katsuya, Takayoshi Ohkubo, Takuo Hirose, Ryusuke Inoue, Hirohito Metoki, Masahiro Kikuya, Taku Obara, Hironori Hanada, Lutgarde Thijs, Tatiana Kuznetsova, Yuichi Noguchi, Ken Sugimoto, Mitsuru Ohishi, Shigeto Morimoto, Takeshi Nakahashi, Shin Takiuchi, Toshihiko Ishimitsu, Takuya Tsuchihashi, Masayoshi Soma, Jitsuo Higaki, Hideo Matsuura, Tatsuo Shinagawa, Toshiyuki Sasaguri, Tetsuro Miki, Kazuo Takeda, Kazuaki Shimamoto, Michio Ueno, Naohisa Hosomi, Jyouji Kato, Norio Komai, Shunichi Kojima, Kazuhiro Sase, Toshiyuki Miyata, Hitonobu Tomoike, Yuhei Kawano, Toshio Ogihara, Hiromi Rakugi, Jan A Staessen, Yutaka Imai.   

Abstract

BACKGROUND: Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB).
METHODS: We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10(-4), we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine.
RESULTS: SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication.
CONCLUSION: Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24192120     DOI： 10.2217/pgs.13.161

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  18 in total

Review 1.  ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.

Authors:  Peter T Nelson; Gregory A Jicha; Wang-Xia Wang; Eseosa Ighodaro; Sergey Artiushin; Colin G Nichols; David W Fardo
Journal:  Ageing Res Rev       Date:  2015-07-28       Impact factor: 10.895

Review 2.  Precision medicine in cardiology.

Authors:  Elliott M Antman; Joseph Loscalzo
Journal:  Nat Rev Cardiol       Date:  2016-06-30       Impact factor: 32.419

3.  KATP Channel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis.

Authors:  José M Vidal-Taboada; Marco Pugliese; Maria Salvadó; Josep Gámez; Nicole Mahy; Manuel J Rodríguez
Journal:  Mol Neurobiol       Date:  2018-02-28       Impact factor: 5.590

Review 4.  An update on the pharmacogenetics of treating hypertension.

Authors:  V Fontana; M R Luizon; V C Sandrim
Journal:  J Hum Hypertens       Date:  2014-08-28       Impact factor: 3.012

Review 5.  A personal history of research on hypertension From an encounter with hypertension to the development of hypertension practice based on out-of-clinic blood pressure measurements.

Authors:  Yutaka Imai
Journal:  Hypertens Res       Date:  2022-09-08       Impact factor: 5.528

6.  Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.

Authors:  Michael T Eadon; Sri H Kanuri; Arlene B Chapman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-03

7.  Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.

Authors:  Timo P Hiltunen; Kati M Donner; Antti-Pekka Sarin; Janna Saarela; Samuli Ripatti; Arlene B Chapman; John G Gums; Yan Gong; Rhonda M Cooper-DeHoff; Francesca Frau; Valeria Glorioso; Roberta Zaninello; Erika Salvi; Nicola Glorioso; Eric Boerwinkle; Stephen T Turner; Julie A Johnson; Kimmo K Kontula
Journal:  J Am Heart Assoc       Date:  2015-01-26       Impact factor: 5.501

8.  Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium.

Authors:  Joshua C Bis; Colleen Sitlani; Ryan Irvin; Christy L Avery; Albert Vernon Smith; Fangui Sun; Daniel S Evans; Solomon K Musani; Xiaohui Li; Stella Trompet; Bouwe P Krijthe; Tamara B Harris; P Miguel Quibrera; Jennifer A Brody; Serkalem Demissie; Barry R Davis; Kerri L Wiggins; Gregory J Tranah; Leslie A Lange; Nona Sotoodehnia; David J Stott; Oscar H Franco; Lenore J Launer; Til Stürmer; Kent D Taylor; L Adrienne Cupples; John H Eckfeldt; Nicholas L Smith; Yongmei Liu; James G Wilson; Susan R Heckbert; Brendan M Buckley; M Arfan Ikram; Eric Boerwinkle; Yii-Der Ida Chen; Anton J M de Craen; Andre G Uitterlinden; Jerome I Rotter; Ian Ford; Albert Hofman; Naveed Sattar; P Eline Slagboom; Rudi G J Westendorp; Vilmundur Gudnason; Ramachandran S Vasan; Thomas Lumley; Steven R Cummings; Herman A Taylor; Wendy Post; J Wouter Jukema; Bruno H Stricker; Eric A Whitsel; Bruce M Psaty; Donna Arnett
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

9.  An intronic PICALM polymorphism, rs588076, is associated with allelic expression of a PICALM isoform.

Authors:  Ishita Parikh; Christopher Medway; Steven Younkin; David W Fardo; Steven Estus
Journal:  Mol Neurodegener       Date:  2014-08-29       Impact factor: 18.879

10.  Does Antihypertensive Drug Class Affect Day-to-Day Variability of Self-Measured Home Blood Pressure? The HOMED-BP Study.

Authors:  Kei Asayama; Takayoshi Ohkubo; Tomohiro Hanazawa; Daisuke Watabe; Miki Hosaka; Michihiro Satoh; Daisaku Yasui; Jan A Staessen; Yutaka Imai
Journal:  J Am Heart Assoc       Date:  2016-03-23       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.